Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fusion Pharmaceuticals Inc.

http://fusionpharma.com/

Latest From Fusion Pharmaceuticals Inc.

Will Actinium Be Big Pharma’s Next Radiopharmaceuticals Acquisition?

With big pharma on a radiopharmaceuticals buying spree, New York-based Actinium Pharmaceuticals has been pointed to as the next potential takeout target.

Market Intelligence Commercial

Novartis Looks To Maintain A Lead In Radiopharmaceuticals With Mariana Takeout

The acquisition of Mariana will complement Novartis’s lutetium-based radioligand therapies with candidates using actinium. Lilly, Bristol and AstraZeneca all have made recent high-priced buys in the space.

M & A Business Strategies

AstraZeneca Looks To Many Modalities In Cancer

Mohit Manrao, head of AstraZeneca’s US oncology business unit, explained the company’s diverse approach in an interview, including investments in ADCs, cell therapy and radiopharmaceuticals.

Cancer Business Strategies

Q1 2024 Posts Big M&A Total Led By Novo Holdings’ Catalent Takeout

The $16.5bn deal, intended to increase Novo Nordisk’s production of semaglutide-containing products, led a $36bn-plus quarter for M&A transactions, according to Evaluate.

Evaluate Data M & A
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
  • Biotechnology
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register